Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06655441 · ClinicalTrials.gov registry record · Phase 4
The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function
A Phase 4 study, sponsored by Southern California College of Optometry at Marshall B. Ketchum University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT06655441: Recruiting Phase 4 study, sponsored by Southern California College of Optometry at Marshall B. Ketchum University.
NCT06655441 is a Phase 4 study that is actively recruiting participants, run by Southern California College of Optometry at Marshall B. Ketchum University. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06655441, a Phase 4 study, is actively recruiting participants, sponsored by Southern California College of Optometry at Marshall B. Ketchum University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the effects of trehalose, an ingredient found in commercially available artificial tears, on the corneal barrier function. The investigators will assess corneal dryness and measure the relative corneal epithelial "barrier" function (the degree to which the cornea can prevent penetration of sodium fluorescein dye into the eye) after using eye drops that contain 3% trehalose for one month.
Primary Outcome
The investigators will measure the relative corneal epithelial barrier function (the degree to which the cornea can prevent penetration of sodium fluorescein dye into the eye) after using eye drops that contain 3% trehalose for one month.
Interventions
- DRUG 3% trehalose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2027-04 |
| Phase | Phase 4 |
What NCT06655441 shows while recruiting
NCT06655441 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which 3% trehalose is the first listed.
NCT06655441 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06655441 about?
NCT06655441 is a clinical study titled "The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function". The purpose of this research study is to evaluate the effects of trehalose, an ingredient found in commercially available artificial tears, on the corneal barrier function. The investigators will assess corneal dryness and measure the relative corneal epithelial "barrier" function (the degree to whi...
What is the current status of trial NCT06655441?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2026-03-01. Estimated completion is 2027-04.
What interventions are being tested in trial NCT06655441?
The interventions under investigation include: 3% trehalose (DRUG).
Who is sponsoring clinical trial NCT06655441?
This trial is sponsored by Southern California College of Optometry at Marshall B. Ketchum University, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06655441's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI